Study of the Expression of ALDH1 and CD44 Stem Cell Markers in Male Breast Cancers

HTML  Download Download as PDF (Size: 419KB)  PP. 174-179  
DOI: 10.4236/ojpathology.2013.34032    3,796 Downloads   6,051 Views  

ABSTRACT

Aims: Male breast cancer represents <1% of all breast cancers. Cancer stem cell (CSC)s have been associated with tu- mor aggressiveness and drug resistance. CSCs are characterized by CD44 and/or ALDH1 expression. In this study, we investigated their expression in male breast cancer. Method: Two in situ ductal carcinoma (DCIS) and 18 invasive duc- tal carcinoma (IDC) male breast cancer cases were studied with Jefferson IRB approval. Membrane staining of CD44 was scored by the percentage of positivity. Cytoplasmic expression of ALDH1 was considered positive. Results: Ten cases had high CD44 expression, which were all IDC. Both DCIS and in situ component of IDC were CD44 low. ALDH1 was only positive in 15 IDCs. ALDH1+ cells were mostly in the invasive component. Both DCIS cases were negative for ALDH1. Among the 15 ALDH1+ IDCs, five with only invasive component had a higher percentage (aver- age 4.4%) of positive cells compared to the other eight with in situ components (average 2.0%). Metastatic cells in sen- tinel lymph nodes had a similar expression pattern of CD44 and ALDH1 as their primary tumor. Conclusion: CD44 and ALDH1 are expressed in male breast cancers and they are overexpressed in invasive cancer compared to carcinoma in situ. These findings suggest that CSCs play an important role in the progression to invasive carcinoma.

Share and Cite:

P. Gong, B. Boman and J. Palazzo, "Study of the Expression of ALDH1 and CD44 Stem Cell Markers in Male Breast Cancers," Open Journal of Pathology, Vol. 3 No. 4, 2013, pp. 174-179. doi: 10.4236/ojpathology.2013.34032.
Journals Menu
Follow SCIRP
Contact us
+1 323-425-8868
customer@scirp.org
WhatsApp +86 18163351462(WhatsApp)
Click here to send a message to me 1655362766
Paper Publishing WeChat

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.